Compare PACK & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PACK | SLN |
|---|---|---|
| Founded | 1972 | 1994 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 653.6M | 678.0M |
| IPO Year | 2017 | 2010 |
| Metric | PACK | SLN |
|---|---|---|
| Price | $5.08 | $13.27 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 5 |
| Target Price | $6.50 | ★ $42.60 |
| AVG Volume (30 Days) | 595.9K | ★ 1.6M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $395,000,000.00 | $559,000.00 |
| Revenue This Year | $9.29 | N/A |
| Revenue Next Year | $8.35 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.08 | N/A |
| 52 Week Low | $3.22 | $4.19 |
| 52 Week High | $7.81 | $17.58 |
| Indicator | PACK | SLN |
|---|---|---|
| Relative Strength Index (RSI) | 37.34 | 57.07 |
| Support Level | $4.73 | $5.24 |
| Resistance Level | $5.71 | $17.58 |
| Average True Range (ATR) | 0.22 | 1.01 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 24.62 | 37.82 |
Ranpak Holdings Corp is a provider of environmentally sustainable, systems-based, product protection solutions for e-Commerce and industrial supply chains. The company offers a full suite of protective packaging systems and paper consumables. The group generates revenue by providing its PPS systems and paper consumables to customers, which include direct end-users and a network of exclusive paper packaging solution distributors, and by providing end-of-line automation systems that solve challenges, including optimization, customization, and efficiency. It has two segments, North America and Europe/Asia.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.